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Abstract  
Background: Approximately forty percent of all dopaminergic neurons in SNpc are located in five 
dense neuronal clusters, named nigrosomes. T2- or T2*-weighted images are used to delineate the 
largest nigrosome, named nigrosome-1. In these images, nigrosome-1 is a hyperintense region in 
the caudal and dorsal portion of the T2- or T2*-weighted substantia nigra. In PD, nigrosome-1 
experiences iron accumulation, which leads to a reduction in T2-weighted hyperintensity. Here, we 
examine neuromelanin-depletion and iron deposition in regions of interest (ROIs) derived from 
quantitative-voxel based morphometry (qVBM) on neuromelanin-sensitive images and compare 
the ROIs with nigrosome-1 identified in T2*-weighted images.  
Methods: Neuromelanin-sensitive and multi-echo gradient echo imaging data were obtained. R2* 
was calculated from multi-echo gradient echo imaging data. qVBM analysis was performed on 
neuromelanin-sensitive images and restricted to SNpc. Mean neuromelanin-sensitive contrast and 
R2* was measured from the resulting qVBM clusters. Nigrosome-1 was segmented in T2*-weighted 
images of control subjects and its location was compared to the spatial location of the qVBM 
clusters.  
Results: Two bilateral clusters emerged from the qVBM analysis. These clusters showed reduced 
neuromelanin-sensitive contrast and increased mean R2* in PD as compared to controls. Cluster-1 
from the qVBM analysis was in a similar spatial location as nigrosome-1, as seen in T2*-weighted 
images. 
Conclusion: qVBM cluster-1 shows reduced neuromelanin-sensitive contrast and is in a similar 
spatial position as nigrosome-1. This region likely corresponds to nigrosome-1 while the second 
cluster may correspond to nigrosome-2. 
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Introduction 
The substantia nigra is a paired midbrain structure comprised of two substructures, 
substantia nigra pars compacta (SNpc) and substantia nigra pars reticulata. SNpc contains dense 
clusters of neuromelanin-containing dopaminergic neurons [1]. SNpc is profoundly affected in the 
prodromal stages of Parkinson’s disease (PD) where up to 50% of melanized neurons in SNpc are 
lost by the time of clinical presentation [2].  
The anatomy of SNpc and the distribution of its dopaminergic neurons can be organized 
based on calbindin D28K immunostaining. Within SNpc there are five D28K negative subregions 
containing clusters of melanized dopamine neurons, labeled nigrosomes 1-5. Those subregions that 
are calbindin D28K positive lack these dense clusters of melanized neurons and are referred to as 
matrix [3]. The largest nigrosome, nigrosome-1, exhibits the most profound PD-related 
neurodegeneration with up to 98% neuronal loss. The SNpc region with the second highest degree 
of neuronal loss is nigrosome-2 in PD, followed by nigrosomes-4, 3, and 5 [4]. Other work found 
the greatest loss of dopaminergic neurons centered in the lateral and ventral portions of SNpc, a 
subregion containing nigrosome-1 [5, 6]. 
Iron deposition has been found in conjunction with PD-related neuronal loss in SNpc [7]. 
T2*-weighted images are sensitive to iron and regions with high iron content appear hypointense 
in these images and these images have been employed to detect loss of hyperintensity associated 
with iron deposition in nigrosome-1. In T2*-weighted images, nigrosome-1 can be seen as a 
relatively hyperintense region in the caudal and dorsal portion of the T2*-hypointense substantia 
nigra in control subjects [8]. This results in an overall appearance resembling a swallow tail [8]. 
However, hypointense signal is observed in this region in PD, and the swallow-tail appearance is 
lost due to neurodegeneration-associated iron deposition [9-11]. 
T2*-weighted images are not sensitive to neuromelanin, and therefore accurate delineation 
of SNpc is difficult in these images [12]. Incidental or explicit magnetization transfer effects can 
be used to generate neuromelanin-sensitive contrast and delineate SNpc [13, 14].  Studies localizing 
SNpc with neuromelanin-sensitive contrast found a reduction in neuromelanin-sensitive signal [15] 
or increased iron deposition [16] in the lateral-ventral region of SNpc. The results of these studies 
may reflect neurodegeneration in nigrosome-1. However, the spatial relationship between 
nigrosome-1 and the SNpc defined with neuromelanin-sensitive contrast, and the manifestations of 
nigrosomal neurodegeneration in neuromelanin-sensitive images are largely unexplored.  
In this work, a voxel-based analysis is used to determine spatial locations in SNpc most 
sensitive to PD-related neuronal loss. We further examine the location of nigrosome-1 with respect 
to the neuromelanin-sensitive substantia nigra (SNpc) and use nigrosome-1 to interpret significant 
clusters from the voxel-based analysis. 
Materials and Methods 
Sixty-one subjects (31 PD and 30 control) participated in this study. Data from 3 PD and 2 
control subjects were excluded due to motion artifacts resulting in a final sample size of 56 subjects 
(28 PD and 28 control). All subjects participating in the study gave written informed consent in 
accordance with local institutional review board regulations. PD subjects were recruited from the 
Emory University Movement Disorders Clinic and clinically diagnosed with PD according to the 
UK Brain Bank criteria [17]. PD patients had early to moderate disease with a Unified Parkinson’s 
Disease Rating Scale Part III (UPDRS-III) motor score of ≤25 in the ON medication state. Control 
subjects were recruited from a cohort of individuals without major neurological diagnoses followed 
by the Emory Alzheimer’s Disease Research Center. Specific exclusion criteria included the 
following: 1) patients showing symptoms or signs of secondary or atypical parkinsonism [18], 2) 
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controls were excluded if they scored ≤26 on the Montreal Cognitive Assessment (MOCA) 
indicating cognitive impairment, 3) any history of vascular territorial stroke, epilepsy, multiple 
sclerosis, neurodegenerative disease (aside from PD), peripheral neuropathy with motor deficits, 
parenchymal brain tumor, hydrocephalus, or schizophrenia, 4) treatment with an antipsychotic drug 
(other than quetiapine at a dose less than 200mg daily), or 5) if there were any contraindications to 
MRI imaging.  
Demographic information including gender, age and education, was collected for each 
subject and is shown in Table 1. Participants in both the PD and control groups underwent UPDRS-
III examination by a fellowship-trained movement disorders neurologist. PD patients were 
examined and underwent imaging in the ON medication state. 
Variable HC (n=28) 
PD 
(n=28) p Value 
Gender (M/F) 17/11 15/13 0.45 
Age (yrs) 64.8±5.2 62.3±9.2 0.22 
Education (yrs) 16.8±2.6 15.9±2.9 0.30 
L-DOPA equivalent  –– 626±448 –– 
UPDRS-III score 2.4±2.3 22.4±8.0 <10-4 
Hoehn and Yahr –– 2.0±0.4 –– 
Disease Duration (yrs) –– 4.7±4.5 –– 
Table 1. Demographic information and clinical characteristics of PD patients and healthy controls in the 
cohort used in this analysis. Data are presented as mean ± standard deviation. L-DOPA – levodopa; UPDRS 
- Unified Parkinson's Disease Rating Scale. 
 
Image Acquisition 
Data were acquired on a 3T MRI scanner (Prisma Fit, Siemens Healthineers, Malvern, PA) 
using a 64-channel receive only coil. Images from a T1-weighted MP-RAGE sequence (echo time 
(TE)/repetition time (TR)/inversion time=3.02/2600/800 ms, flip angle (FA)=8°, voxel 
size=0.8×0.8×0.8 mm3) were used for registration from subject space to common space. 
Neuromelanin-sensitive data were acquired using a magnetization-prepared 2D gradient recalled 
echo sequence: TE/TR=3.10/354 ms, 416×512 imaging matrix, voxel size=0.39×0.39×3 mm3, 15 
slices, FA = 40°, 7 measurements, magnetization transfer preparation pulse (300°, 1.2 kHz off-
resonance) [13]. The seven measurements were saved individually for offline processing. 
Multiecho data were collected with a 6-echo 3D gradient recalled echo sequence: 
TE1/∆TE/TR=4.92/4.92/50 ms, FOV=220×220 mm2, matrix size of 448×336×80, slice thickness=1 
mm, and GRAPPA acceleration factor=2.  
Standard space transformation 
Imaging data were analyzed with FMRIB Software Library (FSL). A transformation was 
derived from individual subject space to Montreal Neurological Institute (MNI) T1-weighted 
common space using FMRIB’s Linear Image Registration Tool and FMRIB’s Nonlinear Image 
Registration Tool in the FSL software package [19]. The procedure for this transformation is as 
follows: first, the T1-weighted image was skull stripped using the brain extraction tool in FSL. 
Next, brain extracted T1-weighted images were aligned with the MNI brain extracted image using 
an affine transformation. Finally, a nonlinear transformation was used to generate a transformation 
from individual T1-weighted images to T1-weighted MNI common space.  
Neuromelanin SNpc atlas 
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 A SNpc neuromelanin atlas in MNI space was used in this study to localize SNpc for the 
voxel-based analysis. The atlas was created from a cohort of 76 healthy older participants (mean 
age: 66.6 years ± 6.4 years) using a process similar to those outlined in [16].  
R2* map creation 
 R2* is defined as the inverse of the transverse relaxation rate (1/T2*) and is measured from 
a multi-echo gradient echo pulse sequence. R2* varies linearly with iron content and can be used as 
a marker of brain iron in vivo [20, 21]. R2* values were estimated voxel-wise using a custom script 
in MATLAB by fitting a monoexponential model to the gradient echo images using the following 
equation: 𝑆"(𝑇𝐸) = 𝑆(exp	(−𝑅/∗𝑇𝐸)       [1] 
where S0 denotes a fitting constant and Si denotes the signal of a voxel at the ith echo time. The 
resulting R2* map was aligned to the T1-weighted image using a transform derived from the 
magnitude image from the first echo. Finally, mean R2* was calculated in the clusters from the 
quantitative voxel based analysis described in later sections.  
Neuromelanin-sensitive image processing 
Imaging data in this section were analyzed with FSL. First, images from the seven 
measurements with neuromelanin-sensitive contrast from the magnetization-transfer prepared 
gradient echo sequence were registered to the first image using a linear transformation tool and 
averaged. The averaged image was used in the subsequent analysis. A transformation between the 
resulting magnetization transfer prepared gradient echo image and T1-weighted image was derived 
using a rigid body transform with boundary-based registration cost function. The quality of 
registration was checked for each subject and no significant misregistrations were observed across 
the sample.  
 Contrast from the magnetization transfer preparation pulse, denoted magnetization transfer 
contrast (MTC), was estimated using the following equation: 𝑀𝑇𝐶 = 𝐼 − 𝐼456 /𝐼456 
where I denotes the intensity of a voxel in the magnetization transfer prepared gradient echo image 
and Iref is the mean intensity of a reference region in the magnetization transfer prepared gradient 
echo image. To ensure consistent placement of reference region in the magnetization transfer 
prepared gradient echo images across subjects, a reference region was drawn in the cerebral 
peduncle in MNI T1-weighted common space and then transformed to individual magnetization 
transfer prepared gradient echo images. A typical registration is seen in supplemental Figure S1. 
The resulting MTC maps were then transformed to MNI common space for voxel-based 
morphometry analysis.  
Quantitative Voxel Based Analysis 
 In contrast to standard voxel-based morphometry analysis, which uses T1-weighted images 
to ascertain regions exhibiting reduced T1-contrast, quantitative voxel-based morphometry 
(qVBM) is applied to semi-quantitative MRI images, such as MTC images (i.e. neuromelanin-
sensitive images), and allows for spatial regions exhibiting disease-related changes to be 
ascertained.  Voxel-wise differences in MTC, generated and transformed to common space in the 
previous section, were found using qVBM [22]. To correct for multiple comparisons over space, 
we used permutation-based non-parametric inference with the framework of the general linear 
model with 5000 permutations. Results were considered significant for p<0.05 (family-wise error 
corrected) after initial-cluster forming thresholding at p-corrected=0.05. For this analysis, statistical 
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testing was restricted to the control neuromelanin-sensitive SNpc volume. Mean MTC and R2* 
were calculated in the resulting clusters. 
Nigrosome-1 
 Nigrosome-1 was manually segmented in images acquired during the 5th echo of the multi-
echo gradient echo sequence (TE=24 ms) for control subjects. Nigrosome-1 was defined to be the  
 
hyperintense region in slices 2 mm below the lower extent of the red nucleus. Nigrosome-1 for a 
representative control subject is shown in Figure 1A. For each control, nigrosome-1 was 
transformed into MNI space using the procedures defined above and then averaged to create a 
population atlas for nigrosome-1. The nigrosome-1 atlas was then thresholded at a level of 0.5, 
corresponding to 50% of the population in agreement for nigrosome-1, and binarized. 
The Dice similarity coefficient (DSC) was used to assess the closeness nigrosome-1 and 
the first cluster from the qVBM analysis. DSC values of 0 and 1 indicate no overlap and perfect 
overlap between two regions, respectively. DSC is defined as  DSC = 2 ∗ volume(𝑁𝑆1 𝐶1)volume 𝑁𝑆1 + volume(𝐶1) 
where NS1 denotes nigrosome-1 in MNI space and C1 denotes cluster 1 from the qVBM analysis. 
Statistical Analysis 
 All statistical analyses were performed using IBM SPSS Statistics software version 24 
(IBM Corporation, Somers, NY, USA) and results are reported as mean ± standard deviation. As 
nigrosomes exhibit the most profound PD-related neurodegeneration [4], we hypothesize clusters 
showing significant reductions in MTC from the qVBM analysis spatially overlap with  
nigrosomes. To correct for multiple comparisons over space in the qVBM analysis, we used 
permutation-based non-parametric inference with the framework of the general linear model with 
5000 permutations [23]. Within each cluster, group SNpc R2* and MTC comparisons between PD 
patients and controls were made using a one-tailed t-test. A one-tailed t-test is used since the 
direction of expected effects is known based on prior studies, which reported that PD is associated 
with MTC reduction and R2* increase in SNpc [15, 24]. Linear regressions were performed with 
mean R2* and MTC from qVBM clusters with UPDRS-III score and disease duration. A p-value of 
0.05 was considered significant for all statistical tests performed in this work. Receiver operator 
characteristic (ROC) analysis were performed for mean R2* and MTC values in each cluster.  
Results 
There was no difference in age (p=0.22), educational (p=0.30), or sex (p=0.25) distribution 
between PD patients and control subjects. Demographic information is summarized in Table 1.  
 
 
Figure 1. Panel A shows nigrosome-1, seen 
as the hyperintense region embedded in the 
T2-weighted substantia nigra, in a control 
subject. The yellow arrows point to the 
hyperintense region defining nigrosome-1. A 
view of a T2-weighted substantia nigra in a PD 
subject is seen in B. No hyperintense region is 
seen in the T2-weighted substantia nigra of the 
PD subject. Slices in both frames are placed 2 
slices (or 4 mm) below the red nucleus.  
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qVBM analysis 
Analysis of MTC in SNpc with qVBM revealed two bilateral statistically significant 
clusters of reduced MTC in PD patients as compared to controls. The clusters are shown in Figure 
2B. Cluster 1 was located in the lateral and posterior portions of SNpc (left center of mass: Z=-8.8 
mm, Y= -22.2 mm, Z= -15.6 mm; right center of mass: X=-10.2 mm, Y=-22.2 mm, Z=-15.1 mm).  
 
In cluster 1, mean MTC in the PD group was reduced relative to that of the control group (Control: 
0.16±0.03; PD: 0.13±0.03; p=5.0×10-4). Cluster 2 was located in the anterior and medial portions  
of SNpc (left center of mass: X=-4.6 mm, Y=-16.5 mm, Z=-16.9 mm; right center of mass: x= 6.0 
mm, y= -15.7 mm, z= -16.0 mm), and in cluster 2 MTC was also lower in the PD group (Control: 
0.18±0.02; PD: 0.15±0.02; p=8.6×10-5). These results are shown in Figure 3. No correlation was 
observed between ON UPDRS-III score and mean MTC in qVBM cluster 1 (p=0.412, r=0.161) or 
between ON UPDRS-III score and mean MTC in qVBM cluster 2 (p=0.065; r=0.353). 
 Iron deposition in the clusters from the qVBM analysis was examined by measuring mean 
R2* within each cluster. Increases in R2* were observed in qVBM cluster 1 (Control: 26.0 s-1±5.4 
s-1; PD: 30.2 s-1±5.7 s-1; p=0.004) and qVBM cluster 2 (Control: 33.4 s-1±5.6 s-1; PD: 37.0 s-1±5.7 
s-1; p=0.012) of the PD group as compared to controls. No correlation was observed between ON 
UPDRS-III score and mean R2* in VBM cluster 1 (p=0.241, r=0.127) or between ON UPDRS-III 
score and mean R2* in VBM cluster 2 (p=0.109, r=0.220). 
In the ROC analysis, mean MTC outperformed mean R2* as a marker for PD in qVBM 
clusters 1 and 2. Area under the curve (AUC) for mean MTC in VBM clusters 1 and 2 was 0.746 
(standard error (SE)=0.066; 95% confidence interval (CI)=0.616-0.876; p=0.002) and 0.786 
(SE=0.062; 95% CI=0.664-0.907; p=0.0002), respectively. AUC for mean R2* in qVBM cluster 1 
 
Figure 2. A comparison of nigrosome-1 and qVBM clusters in MNI space. Panel A shows the spatial 
position of the nigrosome-1 population mask, as segmented in T2*-weighted images, overlaid on the T1-
weighted MNI template. Clusters from the qVBM analysis overlaid on the T1-weighted MNI template are 
shown in panel B. The SNpc is displayed in blue in both panels. Z values in each slice indicate position in 
MNI space. Nigrosome-1 and qVBM cluster 1 are located in similar spatial locations and have a DSC of 
0.4.  qVBM – quantitative voxel based morphometry; DSC – dice similarity coefficient; MNI – Montreal 
Neurological Institute 
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was 0.691 (SE=0.066; 95% CI=0.555-0.827; p=0.012). Mean R2* in qVBM cluster 2 had an AUC 
of 0.661 (SE=0.073; 95% CI=0.518-0.804; p=0.035). 
 
Nigrosome-1 in T2*-weighted images 
In T2*-weighted images, nigrosome-1 is seen as a hyperintense region embedded in the 
T2*-weighted substantia nigra [8]. Nigrosome-1 was observed in 27 of the 28 controls participating 
in this study, but was not visible in 26 of the 28 subjects in the PD group. After transformation of 
the control nigrosome-1 masks to MNI space, thresholding and binarization, the center of mass for 
the control nigrosome-1 in MNI space was (X=10.9 mm, Y=-21.6 mm, Z=-14.6 mm) and (X=-10.1 
mm, Y=-22.0 mm, Z=-14.9 mm) for the right and left sides (see Figure 2A), respectively. 
Interestingly, nigrosome-1 and cluster 1 from the qVBM analysis are located in highly similar 
anatomical positions, with a difference in center of mass between nigrosome-1 and MTC cluster 1 
of 1.4 mm and 1.1 mm for the left and right sides, respectively. The DSC for the binarized 
nigrosome-1 mask and qVBM cluster 1 is 0.40, indicating overlap between qVBM cluster 1 and 
nigrosome-1.  
 
 
Figure 3. A comparison of mean MTC in 
qVBM cluster 1 (A) and mean MTC in 
qVBM cluster 2 (B) in PD and control 
groups. Significant reductions in MTC are 
seen between PD and control groups in both 
cluster 1 (p=5.0×10-4) and cluster 2 
(p=8.6×10-5). Panels (C) and (D) show a 
comparison of mean MTC and mean R2* in 
qVBM cluster-2 for PD and control groups, 
respectively. Significant increases in R2* 
are seen between PD and control groups in 
both cluster 1 (p=0.004) and cluster 2 
(p=0.012). MTC – magnetization transfer 
contrast; qVBM – quantitative voxel based 
morphometry  
 
Discussion 
Delineation of nigrosome-1 in magnetization transfer prepared images is difficult due to 
its small size and the relatively low signal to noise ratio of these images. In this work, we applied 
a data-driven approach (qVBM analysis on NM-sensitive images) to ascertain PD-related 
reductions in NM-content in SNpc.  Two clusters of significance were found in the qVBM analysis. 
Cluster 1 was located in the lateral-ventral tier, and cluster 2 was located medially and ventral to 
cluster 1. Reductions in MTC and increases in R2* were observed in both clusters. The increase in 
R2* in cluster-1 is likely associated with the disappearance of nigrosome-1 in T2*-weighted images 
of PD patients, given the high spatial correspondence between cluster 1 and nigrosome-1 of control 
subjects.  
T2*- weighted images are widely used to delineate nigrosome-1 [9-11]. Consistent with 
earlier results [9-11], in T2*-weighted images, nigrosome-1 was seen in the majority of control 
subjects (27 of 28 controls) and was absent in PD (26 of 28 patients). In PD, nigrosome-1 is 
associated with a loss of dorsolateral nigral hyperintensity in T2* weighted images [25]. The 
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description of this spatial position reflects the anatomic orientation from the perspective of 
substantia nigra as seen in T2*-weighted images. From the anatomic orientation of substantia nigra 
in neuromelanin-sensitive images, nigrosome-1 is located in the lateral-ventral portion of the 
neuromelanin-defined SNpc (Figure 2A). Thus, loss of hyperintensity in nigrosome-1 from iron 
deposition and T2*-weighted hypointensity observed in the lateral-ventral SNpc [16] likely reflect 
identical regions of PD degeneration.  
qVBM analysis on neuromelanin-sensitive images revealed two clusters of reduced 
neuromelanin-sensitive contrast. Cluster 1 from the qVBM analysis is located in the lateral-ventral 
portion of SNpc. Interestingly, this cluster shows substantial overlap in MNI-space with the 
nigrosome-1 control population map and reductions in MTC may indicate a loss of dopaminergic 
neurons in nigrosome-1 [26]. Studies examining PD-related SNpc volume or contrast loss found a 
reduction of neuromelanin-sensitive contrast in the posterior portion of SNpc [27, 28]. Consistent 
with these findings, earlier work examining lateral-ventral tier SNpc ROIs found reduced MTC in 
this region of PD subjects [15]. These results accord with histological studies showing the greatest 
amount of PD-related neuronal loss in SNpc occurs in the lateral-ventral tier of SNpc [2, 5, 6]. 
Further, as nigrosome-1 is in the lateral-ventral tier of SNpc, the loss of volume and MTC reported 
in the aforementioned imaging studies may be due to neuronal loss in nigrosome-1. 
Although nigrosome-1 has received the most attention as a potential PD biomarker, 
nigrosomes 2-5 also experience loss of dopaminergic neurons. To date, delineation of nigrosomes 
2-5 have been achieved in T2-weighted images at ultra-high field strengths [10, 29]. Like 
nigrosome-1, nigrosomes 2-5 are seen as hyperintense regions embedded in the T2-weighted 
substantia nigra [10, 29]. In particular, nigrosome-2 is positioned medial and ventral to nigrosome-
1 in histological and imaging studies [3, 10]. Interestingly, similar spatial positioning is seen in 
clusters emerging from the qVBM analysis with cluster 2 positioned in a medial and ventral 
position to cluster 1. Thus, reductions in MTC in cluster 2 from the qVBM analysis may reflect 
neuronal loss in nigrosome-2. Taken together, these results suggest that reductions in 
neuromelanin-sensitive contrast in PD largely occur in the nigrosomes, and may manifest as 
reductions in SNpc volume, lateral-ventral MTC contrast, or SNpc width in PD, as reported in 
earlier neuromelanin-sensitive studies using explicit or incidental magnetization transfer effects 
[15, 27, 30-33]. 
There are some caveats in the present. First, UPDRS-III evaluation was conducted in the 
ON state and OFF state evaluations are not available. The lack of statistically significant 
correlations between mean R2* and mean MTC values in qVBM clusters with clinical motor 
severity may be due to measurement of UPDRS-III in the ON state. Second, neuromelanin-sensitive 
images have low signal to noise ratio, and smoothing of the neuromelanin-sensitive image may 
introduce uncertainty in the spatial position of qVBM cluster 1 and reduce the overlap with 
nigrosome-1.   
Conclusion 
In summary, we found PD-related reductions in MTC in two clusters in SNpc from the 
qVBM analysis and PD-related increases in R2* were observed in both clusters. Cluster 1 spatially 
overlaps with nigrosome-1, as defined in T2*-weighted images. Reductions in MTC within both 
clusters likely reflect a loss of melanized neurons. These results suggest that reductions in MTC 
largely occur in the nigrosomes and volume loss shown in earlier neuromelanin-sensitive studies 
reflect neuromelanin depletion in nigrosomes.  
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